The results aren’t all positive – Trelegy wasn’t able to improve on Relvar/Breo when it came to reducing asthma exacerbations and two other doses of Trelegy didn’t perform better than the ...

Deterioration of Disease and Acute Episodes Do not initiate Trelegy Ellipta in patients with rapidly deteriorating or potentially life-threatening episodes of COPD or asthma; use in this setting ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

Trelegy Ellipta has Food and Drug Administration (FDA) approval to treat asthma and chronic obstructive pulmonary disease (COPD) in adults. COPD is a collection of different lung conditions ...

Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to ...